Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer

Abstract Background Pancreatic cancer (PDAC) often responds poorly to chemotherapy, represents an unmet clinical need and new therapeutic approaches are urgently required. Desmoplasia is a hallmark of PDAC. Multiple preclinical studies suggest cancer associated fibroblasts (CAF) support cancer growt...

Повний опис

Бібліографічні деталі

Автори:	David Easty, Ray McDermott, Adrian G. Murphy, Liam Grogan, Patrick G. Morris, Oscar S. Breathnach, Keith Egan, Sinead Toomey, Anne Horgan, Derek Power, Nemer Osman, Imelda Parker, Vicky Donachie, Anna Shevlin, Aisling Barrett, Marc Nolan, Jacinta Marron, Christine J. Farr, Bryan T. Hennessy
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2026-01-01
Серія:	BMC Cancer
Предмети:	Stromal targeting Vitamin D receptor agonist Hypercalcaemia
Онлайн доступ:	https://doi.org/10.1186/s12885-025-14512-2
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!